RxDoctor Payments Data

Thomas Patrianakos, DO

Ophthalmology · Chicago, ILNPI 1073530929

Payments from drug & device makers

$9,255in general payments, 2019–2025

Across 117 payments — averaging $79.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Glaukos Corporation$2K
  • Sight Sciences, Inc.$1K
  • NEW World Medical,inc.$1K
  • AbbVie$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$235
  • plus $602 from 8 others

What the payments were for

  • Consulting fees$1,77519%
  • Food & beverage$7,48081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,255 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$288,407
Medicare patients
1,138
Services billed
2,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate229$7,126
SimbrinzaBrinzolamide/Brimonidine Tart16$6,611
Latanoprost607$5,541
Brinzolamide23$5,089
Travoprost28$4,946
VyzultaLatanoprostene Bunod13$4,445
LumiganBimatoprost14$4,153
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat188$2,676
Brimonidine Tartrate203$2,523
Cosopt PfDorzolamide/Timolol/Pf13$2,474
Dorzolamide Hcl154$2,359
Azelastine Hcl35$2,053
Timolol Maleate154$1,545
Acetazolamide38$1,108
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha100$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$2,580$6,61116 claims
Bausch & Lomb Americas Inc.Vyzulta$14$4,44513 claims
AbbVieLumigan$1,200$4,15314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →